CHEMKART INDIA LIMITED
CIN-L51220MH2020PLC338631
403/404 K.L. Accolade, 4th Floor, Above Captain Gym, Nr. R.K. Hospital
Santacruz (E), MUMBAI 400055
Email Id: investors@chemkart.com | Customer Care: +91 8828505052
Website: www.chemkart.com

30th October 2026

To
The Corporate Relations Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400001

Scrip Code: 544442

Dear Sir/Madam,

Subject: Investor Presentation – Un-Audited Financial Results for the Half Year ended 30th September 2026.

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor Presentation based on the Un-Audited Financial Results for the Half Year ended 30th September 2026 which is also uploaded on our website.

Kindly take the same on your record.

For Chemkart India limited

MOHAMMAD ASIM SIDDIQUI
Digitally signed by MOHAMMAD ASIM SIDDIQUI
Date: 2026.10.30 21:24:46 +05'30'

Chemkart India Limited Mumbai

Mohammad Asim Siddiqui
Designation – Chief Financial Officer

Enclosed: A/a

Chemkart®
Ingredients, Simplified!

Chemkart India Ltd

Investor Presentation - October 2026

Disclaimer

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Chemkart India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

- Company Overview
- Industry Overview
- Strategic Overview
- Half-Yearly Financial Performance
- Historical Financial Performance
- Investment Rationale

The Foundation of Our Future

Mission
To drive growth and excellence in food and health ingredients through quality sourcing, trusted partnerships, and innovative, sustainable solutions that empower customer success.

Vision
To be a global leader in end-to-end CDMO solutions and trusted distribution of food, health, and specialty ingredients, delivering quality, trust, innovation, and sustainable growth across the value chain.

Company Snapshot

10+ Product Categories

150+ Ingredients

500+ Trusted Clients

30K Sq.Ft Warehouse

Certifications:
ISO 9001:2015 | FSSAI | ETC |

Pan-India
Distribution Network

(2 Year CAGR)
Revenue: **26.9%**
EBITDA: **17.6%**
PAT: **19.6%**

(FY26)
ROE: **15%**
ROCE: **21%**

About Chemkart

Chemkart India Limited, established in March 2015 and headquartered in Mumbai, is a B2B supplier of high-quality raw ingredients used in the manufacturing of nutritional, sports, and health supplements.

The company serves a broad spectrum of manufacturers across India, offering a diverse range of ingredients including amino acids like L-Leucine, L-Isoleucine, L-Valine, and L-Lysine HCL.

Since inception, the company has built strong relationships with both customers and suppliers and operates on a scalable distribution model, supported by effective inventory forecasting and supply chain responsiveness.



- **Incorporated in 2020** as a private company; became *Chemkart India Limited* in 2024.
- **B2B supplier** of raw ingredients for nutritional, sports, and health supplements.
- **Processes key amino acids & ingredients** like L-Leucine, L-Isoleucine, L-Valine, L-Lysine HCL, and more.
- **In-house blending & grinding facility** ensures product customization and quality control.
- **Strong customer & supplier relationships** built since inception.
- **Focus on operational efficiency**, inventory forecasting, and responsive supply chain management.
- **Serves manufacturers** of finished dietary and wellness supplements across India.
- The Company's business operations are further supported by its subsidiaries: **Easy Raw Materials Private Limited** and **Vinstar Biotech Private Limited.**

Chemkart's Present Journey

2015

Chemkart commenced operations as a proprietorship, laying the foundation for its growth.

2020

Transitioned into Chemkart India Private Ltd, evolving from a proprietorship to a private limited company to strengthen operations.

2021

Established **EZRM** as a **Subsidiary** to tap into new market segments & strengthen Chemkart presence

2022

Expanded logistics footprint with new 30,000 sq. ft. warehouse facility in Bhiwandi to strengthen storage and distribution capabilities.

2023

- Launched Vinstar Biotech as a subsidiary to diversify and broaden business horizons.
- Established presence in SEZ with a dedicated sales unit to scale operations.

2025

Listed on the BSE SME Platform under the name Chemkart India Limited.

Vision 2030: Global Biotechnology Leader

2027

- Commissioning of EZRM SEZ Facility – India's first nutraceutical-focused SEZ hub
- Scale-up of novel technologies: liposomal, microencapsulation, nanoemulsion, beadlets
- Establish export-driven manufacturing foundation
- Establishment of R&D Innovation Center

2028

- Entry into integrated manufacturing of bioactive molecules
- Establishment of global offices – USA, Europe, Middle East

2029

- Full-service CDMO offerings: custom molecules → finished dosage forms

2030

- Leadership as India's #1 CRDMO in Nutraceuticals & Personal Wellness
- Global footprint with 60% manufacturing driven revenues
- Fully integrated solutions: ingredients, formulations, regulatory, supply chain

Transitioning Into Manufacturing

Chemkart India Limited (CIL) announced the commencement of full-scale construction of a greenfield facility at its wholly owned subsidiary, **Easy Raw Materials Pvt. Ltd. (EZRM)**, located in the *JNPT Special Economic Zone (SEZ)*, Maharashtra.

This next-generation nutraceutical CDMO facility is designed for global-scale manufacturing, packaging, and export of health supplements with a strong focus on novel ingredient technologies such as microencapsulation, liposomal delivery systems, and enhanced bioavailability formats.

The nutraceutical formulations from our upcoming SEZ-based facility at JNPT, Maharashtra, are primarily aimed at export markets.

Following the Bhumi Pujan held on July 19, 2025, civil and infrastructure work is now in full swing. The SEZ-based facility is strategically positioned near India's largest container port, offering seamless access to global markets and duty-free benefits under SEZ policy.

Highlights of the EZRM SEZ Facility:

- 4,120 sq.m plot leased for 60 years at JNPA SEZ, Raigad
- Integrated CDMO operations: Formulation, packaging, and global dispatch
- Dosage formats: Tablets, capsules, jars, sachets
- Built-in export readiness: SEZ-compliant labelling, documentation & logistics
- Novel technologies: Microencapsulation, liposomal ingredients, and enhanced bioavailability systems
- Modern infrastructure: QC labs, warehousing, utilities, admin block, and sustainability features

Our upcoming facility JNPA

Projected Outlay for the Manufacturing Facility

Updates On Manufacturing Unit

Easy Raw Materials Private Limited | F1 SEZ, JNPA

Construction Progress Update

RCC Structural Development
Reinforcement and shuttering work for columns from the second slab to the third floor is in progress, alongside ongoing concrete curing activities.

PEB Warehouse Structure
Erection of columns, beams, sub-beams, purlins and bracing is underway, progressing the development of the warehouse structure.

Compound Wall Construction
Blockwork is in progress as part of the facility's boundary infrastructure development.

Manpower Deployment
55

A total of 55 personnel are deployed at the site across project supervision and construction teams to support ongoing execution.

Key Activities Under Execution

- **RCC Column Reinforcement & Shuttering**
- **PEB Warehouse Erection**
- **Concrete Curing**
- **Compound Wall Blockwork**

Current Focus: Advancing structural construction and warehouse development through parallel execution of civil and steel structure activities.

Showcasing Our Strength: Products & Partnerships

Our Leading Product Portfolio
Glycine
Creatine Monohydrate 200 Mesh
Inositol
BCAA 2:1:1 (Leucine, Isoleucine, Valine)
L-Glutamine
L-Carnitine
N-Acetyl L-Cysteine (NAC)
Taurine
L-Glutathione (Reduced)
Whey Protein Concentrate 80%

Clientele at a Glance

SUN PHARMA

Dabur

Anthem BioSciences

Himalaya SINCE 1930

Influx HEALTHTECH LTD.

ALKEM

ON OPTIMUM NUTRITION

GNC LIVE WELL

bLife Since 2011

Domestic Stronghold with Emerging Global Reach



Geographic Revenue Breakup

Export Domestic

Warehousing facility in Bhiwandi, Maharashtra spans 28,259 sq. ft. across three floors, fully equipped for blending, grinding, packing, labelling, and sealing operations.

Robust Storage & Processing Capabilities

150+
Ingredients

30000 Sq.ft
Warehouse

50+
Employee Strength

1.8MT/Day
Grinding Capacity

1.5MT/Day
Blending Capacity

Our Group Companies

Vinstar Biotech Limited

Supports science-led platforms in biotech, life sciences, chemicals, and R&D-driven innovation. Its involvement aligns with Chemkart's vision of building high-impact, sustainable manufacturing capacity in India.

Easy Raw Materials Pvt. Ltd

Focused on the manufacturing & export of high-quality nutraceutical and wellness products, driven by sustainability, automation, R&D excellence & cutting-edge formulation technologies.

Leadership Behind Chemkart

Ankit Shailesh Mehta

Chairman & Managing Director

He holds a Bachelor's degree in (Chemical Engineering) & MBA in (Technology Management). With over 11 years of entrepreneurial experience including 4 years dedicated to the nutraceutical industry, he plays a pivotal role in steering Chemkart's strategic direction and long-term growth. He also oversees group companies such as Profoods Nutrition, Easy Raw Materials, and Vinstar Biotech.

Parul Shailesh Mehta

Promoter & Executive Director

With 9 years of experience in the nutraceutical sector, she brings strong operational and strategic expertise. A science graduate with a Medical Laboratory Technology certification, she has led key functions including procurement, sales, logistics, compliance, and quality. She also plays leadership roles in group companies Profoods Nutrition, Easy Raw Materials, and Vinstar Biotech driving brand strategy, marketing, partnerships, and product line expansion.

Shailesh Vinodrai Mehta

Promoter & Executive Director

A commerce graduate from the University of Bombay, he brings over 30 years of experience in the chemical sector through his proprietorship, Atul Chemicals, where he has led business expansion, quality control, and operational strategy. Appointed to the Board in July 2024 and regularized in September 2024, he also contributes his expertise to the nutraceutical and food supplement sector.

Certifications

ISO 9001:2015 Certified

FSSAI License

ISO 22000:2018 Certified

HALAL Certified

KOSHER Certified

- Company Overview
- Industry Overview
- Strategic Overview
- Half-Yearly Financial Performance
- Historical Financial Performance
- Investment Rationale

India’s Nutraceutical Market to Reach USD 85 Billion by 2033

India’s nutraceutical market is **growing at 10.3% CAGR**, projected to reach USD 85 billion by 2033, backed by rising health-conscious consumer spending.

A wellness-focused middle class and expanding elderly population are driving **sustained demand** for functional and personalized nutrition.

Government incentives like PLI schemes and FSSAI regulations are **boosting confidence** in domestic manufacturing and industry scalability.

India’s Ayurvedic legacy and rising global demand for natural ingredients are positioning it as a **leading nutraceutical export hub**.

Indian Nutraceuticals Market Size (USD Billions)



Indian Nutraceuticals Product Share



Global Nutraceuticals Market Size (USD Billions)



SOURCE: April 2026 Grand View Research

Five Growth Drivers Shaping the Nutraceutical Industry

01 Sports & Performance Nutrition

Rising participation in fitness and organized sport is sustaining demand for creatine, branched-chain amino acids and high-purity performance ingredients.

Chemkart Portfolio:
Creatine Monohydrate | BCAA 2:1:1 | L-Glutamine

02 Protein Fortification & Diversification

Greater protein awareness is widening the use of dairy and amino acid-based proteins across supplements, functional foods and fortified beverages.

Chemkart Portfolio:
Whey Protein Concentrate 80% | Glycine

03 Metabolic & Cognitive Wellness

Lifestyle-related health concerns are driving demand for ingredients supporting energy metabolism, cognitive performance and hormonal balance.

Chemkart Portfolio:
Inositol | Taurine | L-Carnitine

04 Healthy Ageing & Preventive Nutrition

An expanding elderly population and a shift towards preventive healthcare are increasing demand for antioxidant and cellular-health actives.

Chemkart Portfolio:
L-Glutathione (Reduced) | N-Acetyl L-Cysteine (NAC)

05 Advanced Formulation & Delivery Technologies

Microencapsulation, liposomal and bioavailability-enhancing systems are improving ingredient stability and efficacy, driving demand for specialised CDMO capabilities.

Chemkart Positioning:
EZRM SEZ CDMO facility, JNPA (under construction)

Value is shifting from ingredient supply towards formulation and contract manufacturing - the opportunity Chemkart's upcoming EZRM SEZ facility is designed to capture.

- Company Overview
- Industry Overview
- Strategic Overview
- Half-Yearly Financial Performance
- Historical Financial Performance
- Investment Rationale

Present Edge & Future Focus:

Strategic Advantages

Experienced Team:
Strong leadership with deep industry knowledge.

Cost-Efficient Operations:
Lean inventory system reduces cost and improves delivery.

Strong Relationships:
Long-term ties with global suppliers and customers.

High-Margin Focus:
Specializes in profitable specialty and performance chemicals.

Diverse Industry Reach:
Serves pharma, agrochemicals, and personal care sectors.

Path Ahead

Product Expansion:
Our new manufacturing facility marks strategic entry into CDMO, expanding capabilities and offerings.

Vertical Integration:
Enabling scalable growth and margin leadership through in-house, integrated manufacturing.

Enhanced R&D:
Developing customized solutions for diverse client needs.

Policy Advantage:
Benefiting from “Make in India” and PLI schemes to boost manufacturing and exports.

Global Reach:
Expanding client base globally while strengthening existing partnerships.

Driving Growth Through Strategic Outreach

Strengthening customer relationships, global supplier partnerships and technical capabilities to develop recurring business opportunities

Glimpses of Chemkart at industry exhibitions and customer interactions

Strategic Customer Development
Strengthening strategic relationships with nutraceutical, sports nutrition, functional food and health ingredient manufacturers through focused key-account management.

Technical & Application-Led Selling
Supporting ingredient selection, technical evaluations, sampling and customer trials to develop commercially relevant solutions.

Global Supplier Partnerships
Identifying innovative ingredients and strengthening global supplier partnerships to broaden and diversify the product portfolio.

Customer Portfolio Expansion
Expanding cross-selling opportunities within the existing customer base while acquiring new accounts across high-growth applications.

Industry Exhibitions & Market Engagement
Participation in domestic and international trade events to strengthen supplier networks, engage prospective customers and drive business development.

- Company Overview
- Industry Overview
- Strategic Overview
- **Half-Yearly Financial Performance**
- Historical Financial Performance
- Investment Rationale

Management Commentary

Ankit Shailesh Mehta
Chairman & Managing Director

The first half of FY27 has been a landmark period for the Company, with an outstanding all-round performance delivered amid a global operating environment shaped by supply-chain shifts and pricing volatility across key product categories.

In H1 FY27, consolidated revenue almost doubled to INR 20,587 lakhs (+99.4% YoY), nearly matching the Company's entire FY26 revenue in just six months. EBITDA grew 107.5% to INR 2,937 lakhs and PAT grew 122.2% to INR 2,256 lakhs. On a standalone basis, EBITDA margin improved by 150 bps and PAT margin by 210 bps over H2 FY26, reflecting the strength of our business model, disciplined execution and the growing trust of our customers.

Alongside this growth, we continued to invest in our long-term platform, with steady progress on the EZRM SEZ manufacturing facility. This is a key milestone in building India's first nutraceutical-focused SEZ hub and strengthening our export and CDMO competitiveness.

The Company will sharpen its focus on research and development, product innovation and advanced nutraceutical technologies. We see this as the true game-changer for our next phase of growth, enabling us to move up the value chain into high-value, differentiated offerings and build a sustainable competitive edge.

Backed by India's nutraceutical industry growing at a double-digit CAGR in India along with strategic investments and an agile business model, the Company enters H2 FY27 with healthy business visibility and a strong sales and project pipeline, well-positioned to sustain its growth trajectory.

We sincerely thank our investors, customers, partners and employees for their continued trust as we build a scalable, future-ready nutraceutical platform.

Key Financial Highlights











Consolidated Income Statement

Particulars (Rs. Lacs)	H1 FY27	H1 FY26	Y-o-Y	H2 FY26	H-o-H
Revenue from Operations	**20,587.3**	**10,322.6**	**99.4%**	**11,160.4**	**84.5%**
Cost of Materials Consumed	111.3	1,005.2		141.1	
Purchase of Stock in Trade	17,806.3	7,494.4		10,364.9	
Changes in Inventories in Stock in Trade	-904.2	-31.6		-1,191.7	
Employee Expenses	236.6	190.3		170.1	
Other Expenses	400.3	248.7		273.8	
EBITDA	**2,937.0**	**1,415.6**	**107.5%**	**1,402.1**	**109.5%**
EBITDA Margin (%)	**14.3%**	**13.7%**	**60 bps**	**12.6%**	**170 bps**
Other Income	198.1	68.8		-2.3	
Depreciation	23.1	25.3		24.3	
EBIT	**3,112.0**	**1,459.0**	**113.3%**	**1,375.5**	**126.2%**
EBIT Margin (%)	**15.1%**	**14.1%**	**100 bps**	**12.3%**	**280 bps**
Finance Cost	100.6	78.2		67.4	
Profit before Tax	**3,011.4**	**1,380.8**	**118.1%**	**1,308.1**	**130.2%**
Tax	755.5	365.9		357.5	
Minority interest in Profit/(Loss)	-	-0.4		-	
Profit After Tax	**2,255.9**	**1,015.2**	**122.2%**	**950.6**	**137.4%**
PAT Margin (%)	**11.0%**	**9.8%**	**120 bps**	**8.5%**	**250 bps**
EPS (As per Profit after Tax)	18.65	9.50		7.86	

Standalone Income Statement

Particulars (Rs. Lacs)	H1 FY27	H1 FY26	Y-o-Y	H2 FY26	H-o-H
Revenue from Operations	**20,447.1**	**10,208.7**	**100.3%**	**11,050.8**	**85.0%**
Cost of Materials Consumed	111.3	1,005.2		141.1	
Purchase of Stock in Trade	17,669.8	7,382.6		10,270.6	
Changes in Inventories in Stock in Trade	-845.8	-18.8		-1,198.8	
Employee Expenses	204.0	165.4		146.6	
Other Expenses	332.2	226.9		245.0	
EBITDA	**2,975.7**	**1,447.3**	**105.6%**	**1,446.3**	**105.7%**
EBITDA Margin (%)	**14.6%**	**14.2%**	**40 bps**	**13.1%**	**150 bps**
Other Income	215.5	86.2		10.1	
Depreciation	20.3	22.4		21.5	
EBIT	**3,170.9**	**1,511.0**	**109.9%**	**1,434.9**	**121.0%**
EBIT Margin (%)	**15.5%**	**14.8%**	**70 bps**	**13.0%**	**250 bps**
Finance Cost	100.0	78.1		67.2	
Profit before Tax	**3,071.0**	**1,432.9**	**114.3%**	**1,367.7**	**124.5%**
Tax	779.6	365.9		357.5	
Profit After Tax	**2,291.3**	**1,067.0**	**114.7%**	**1,010.2**	**126.8%**
PAT Margin (%)	**11.2%**	**10.5%**	**70 bps**	**9.1%**	**210 bps**
EPS (As per Profit after Tax)	18.94	9.99		8.35	

Consolidated Balance Sheet

Assets (Rs. Lacs)	Sep-26	Mar-26
Non - Current Assets		
a)Property, plant and equipment and Intangible Assets		
i)Property, plant and equipment	817.9	833.8
ii) Intangible Assets	1.2	1.2
iii) Capital Work in Progress	956.9	486.8
b)Non-current investments		
c)Deferred Tax Assets (net)	13.1	-
d)Other Non-current Assets	1,518.0	1,553.5
Total Non - Current Assets	**3,307.3**	**2,875.3**
Current Assets		
a) Inventories	4,376.8	3,472.6
b) Trade receivables	8,949.8	4,997.6
c) Cash and cash equivalents	3,302.0	3,864.5
d) Short term loans and advances	1,845.4	404.6
e) Other current assets	70.4	92.8
Total Current Assets	**18,544.4**	**12,832.2**
Total Assets	**21,851.7**	**15,707.5**

Equity And Liabilities (Rs. Lacs)	Sep-26	Mar-26
Shareholders Funds		
(a) Equity share capital	1,209.9	1,209.9
(b)Reserves and Surplus	14,018.1	11,763.1
(c) Minority Interest		-
Total Equity	**15,228.0**	**12,973.0**
Non - Current Liabilities		
a) Long Term Borrowings	177.0	-
b) Deferred tax liabilities (net)	-	11.2
c) Long term provision	13.8	8.0
Total Non - Current Liabilities	**190.8**	**19.2**
Current Liabilities		
a) Short Term Borrowings	2,029.6	495.3
b) Trade payables		
(i)Total Outstanding dues of Micro & Small Enterprises	76.4	65.3
(ii) Total Outstanding dues Creditors other than Micro & Small Enterprises	3,353.7	1,762.1
c)Other current liabilities	175.4	28.4
d)Short Term Provisions	797.8	364.4
Total Current Liabilities	**6,433.0**	**2,715.4**
Total Equity and Liabilities	**21,851.7**	**15,707.5**

Standalone Balance Sheet

Assets (Rs. Lacs)	Sep-26	Mar-26
Non - Current Assets		
a)Property, plant and equipment and Intangible Assets		
i)Property, plant and equipment	478.2	491.7
ii) Intangible Assets	-	-
b)Non-current investments	990.5	650.5
c)Deferred Tax Assets (net)	-	-
d)Other Non-current Assets	1,513.3	1,513.3
Total Non - Current Assets	**2,981.9**	**2,655.4**
Current Assets		
a) Inventories	4,312.7	3,466.9
b) Trade receivables	8,947.6	4,997.5
c) Cash and cash equivalents	3,239.3	3,649.5
d) Short term loans and advances	2,362.9	921.8
e) Other current assets	90.4	74.5
Total Current Assets	**18,952.8**	**13,110.2**
Total Assets	**21,934.8**	**15,765.6**

Equity And Liabilities (Rs. Lacs)	Sep-26	Mar-26
Shareholders Funds		
(a) Equity share capital	1,209.9	1,209.9
(b)Reserves and Surplus	14,186.9	11,895.9
(c) Minority Interest	-	-
Total Equity	**15,396.8**	**13,105.8**
Non - Current Liabilities		
a) Long Term Borrowings	177.0	-
b) Deferred tax liabilities (net)	11.0	11.2
c) Long term provision	11.8	7.3
Total Non - Current Liabilities	**199.8**	**18.4**
Current Liabilities		
a) Short Term Borrowings	2,029.6	495.3
b) Trade payables		
(i)Total Outstanding dues of Micro & Small Enterprises	76.4	65.3
(ii) Total Outstanding dues Creditors other than Micro & Small Enterprises	3,277.7	1,720.2
c)Other current liabilities	157.2	25.7
d)Short Term Provisions	797.3	334.9
Total Current Liabilities	**6,338.2**	**2,641.4**
Total Equity and Liabilities	**21,934.8**	**15,765.6**

Consolidated Cashflow Statement

Particulars (Rs. Lacs)	Sep-26	Mar-26
Cash Flow from Operating Activities		
Profit before Tax	3,011.4	2,688.9
Adjustment for Non-Operating Items	17.9	224.9
Operating Profit before Working Capital Changes	**3,029.3**	**2,913.8**
Changes in Working Capital	-4,555.6	-2,418.1
Cash Generated/Used from Operations	**-1,526.3**	**495.7**
Less: Direct Taxes paid	-344.2	-768.2
Net Cash from Operating Activities	**-1,870.5**	**-272.5**
Cash Flow from Investing Activities	**-302.5**	**-470.6**
Cash Flow from Financing Activities	**1,610.4**	**4,340.8**
Net Increase/(Decrease) in Cash and Cash equivalents	**-562.5**	**3,581.4**

Standalone Cashflow Statement

Particulars (Rs. Lacs)	Sep-26	Mar-26
Cash Flow from Operating Activities		
Profit before Tax	3,071.0	2,800.6
Adjustment for Non-Operating Items	-4.2	178.5
Operating Profit before Working Capital Changes	**3,066.8**	**2,979.1**
Changes in Working Capital	-4,527.8	-2,602.9
Cash Generated/Used from Operations	**-1,461.0**	**376.2**
Less: Direct Taxes paid	-344.1	-721.2
Net Cash from Operating Activities	**-1,805.1**	**-345.0**
Cash Flow from Investing Activities	**-216.1**	**-608.8**
Cash Flow from Financing Activities	**1,611.0**	**3,732.2**
Net Increase/(Decrease) in Cash and Cash equivalents	**-410.2**	**3,371.2**

- Company Overview
- Industry Overview
- Strategic Overview
- Half-Yearly Financial Performance
- **Historical Financial Performance**
- Investment Rationale

Segment-Wise Revenue Contribution







Amino Acids | Herbal Extract | Health Supplement | Nucleotide | Protein | Sports Nutrition | Vitamin | Other

Product Category	FY25	FY26	H1 FY27
Amino Acids	9,025.45	10,320.2	10,286.2
Health Supplement	2,410.53	2,414.1	1,421.0
Herbal Extract	331.78	418.1	300.0
Nucleotide	179.31	187.7	365.4
Protein	618.82	490.3	1,726.5
Sports Nutrition	6,755.84	6,562.7	5,933.5
Vitamin	465.28	488.0	129.5
Other	540.84	378.5	425.1
Total	**20,327.85**	**21,259.5**	**20,587.3**

Key Financial Highlights











Consolidated Numbers

- Company Overview
- Industry Overview
- Strategic Overview
- Half-Yearly Financial Performance
- Historical Financial Performance
- Investment Rationale

Investment Rationale

Profitable Product Mix

Specialty chemicals and nutraceuticals across pharma, personal care, and B2B segments, offering strong profit potential.

Strong Customer Network

Focused on B2B, building trusted relationships to expand customers and drive sustainable nutraceutical growth.

Greenfield Expansion

Investing in EZRM's greenfield manufacturing project to improve margins, reduce dependency, and support CDMO operations.

China Plus One Strategy

Expanding manufacturing into microencapsulation, liposomal, and bioavailability systems to diversify supply and drive innovation.

Policy Support

Capitalizing on "Make in India" and Production Linked Incentive (PLI) schemes to accelerate domestic manufacturing and expand exports.

Expanding Globally

Expanding presence in existing markets and entering new geographies to boost growth and diversify risks.

Company

Chemkart India Limited

CIN: L51220MH2020PLC338631
Email ID: investors@chemkart.com
Tel: + 91 9136383828
Website: www.chemkart.com

Thank You!

Investor Relations Partner

X-B4 Advisory LLP

Rasika Sawant / Aagam Shah
Tel: +91 95944 57518 / +91 8850166932
Email ID: rasika@x-b4.com / aagam@x-b4.com
Website: www.x-b4.com